The company has reduced its share count over this period, returning value to shareholders through buybacks.
Diluted shares outstanding: 2.77B (2021) → 2.47B (2025)
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
+2.5% YoY
YoY Growth Rate
Slow revenue growth
-21.1% YoY
YoY Growth Rate
Earnings declining
¥1.5B/ year
↑ Rising (+15% vs prior year)
8.6% of revenue
Below sector average (18%)
R&D investment increasing — building for the future
Cash flow positive
¥20.3B cash & investments
Quarterly Free Cash Flow
↑ Burn rate improving
Company generates more cash than it spends — no dilution risk from fundraising
3SBio is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Earnings growing 25%+ a year. The compounder zone.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Interest coverage above 8. Profits cover interest many times over.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E under 10. The price tag is small relative to last year's profit.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Modest yield. The bulk of any return needs to come from price appreciation.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
